OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Want free Kindle ebooks? Sign up to receive the best freebie Kindle ebook deals in your email every day. From our sponsors

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017 Sep 30th 2013, 00:00, by swapnil GlobalData has released its new Opportunity Analyzer report, "Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017". The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit's PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma's FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class. Scope Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management. Analysis of the current and future market competition in the global NASH therapeutics market. Pipeline analysis: comprehensive data split across … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=117923. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/opportunityanalyzer-nonalcoholic-steatohepatitis-nash-opportunity-analysis-and-forecasts-to-2017-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions